Global Intranasal Drug Delivery Devices Market by Device Type (Atomizers, Nasal Sprays, Powders), by Application (Pain Management, Vaccination, Allergies), by End-Use Industry (Hospitals, Homecare), and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Intranasal Drug Delivery Devices Market was valued at USD 5.1 Billion in 2024-e and will surpass USD 9.4 Billion by 2030; growing at a CAGR of 10.8% during 2025 - 2030.

The Intranasal Drug Delivery Devices Market is experiencing significant growth due to the increasing adoption of non-invasive drug delivery methods, which offer benefits such as faster onset of action and ease of use. These devices deliver drugs through the nasal cavity, bypassing the digestive system and liver metabolism, which allows for quicker absorption and more effective treatment. The rise in chronic conditions like allergies, pain, and the need for rapid vaccination solutions is driving the demand for intranasal drug delivery systems.

These devices are gaining traction in various therapeutic areas due to their ability to provide a convenient and effective alternative to oral and injectable forms of medication. With advancements in device technologies and the growing focus on patient-centric treatments, the intranasal drug delivery market is poised for continued growth. The market is also benefiting from increased investments in the research and development of new drug formulations for nasal delivery, alongside a growing trend toward needle-free drug administration.

Nasal Sprays Segment Leads the Market owing to their Widespread Use, Convenience, And Efficacy

The nasal sprays segment is the largest in the intranasal drug delivery devices market, owing to their widespread use, convenience, and efficacy. Nasal sprays are ideal for the delivery of a wide variety of drugs, including those for pain management, allergy treatments, and vaccination. Their ease of use, non-invasive nature, and ability to deliver rapid drug absorption have made nasal sprays a preferred option among both patients and healthcare providers.

Nasal sprays are commonly used for treating conditions like allergic rhinitis, asthma, and even for administering vaccines like the flu vaccine. The segment’s growth is also propelled by the continuous development of new and improved nasal spray formulations that are effective in treating a variety of conditions. With increasing awareness about the benefits of intranasal drug delivery, the nasal sprays segment is expected to maintain its leading position in the market.

Pain Management Drives the Largest Application Segment in Acute Pain, is driving the adoption of these Devices

The pain management application segment is the largest within the intranasal drug delivery devices market. The intranasal route offers a rapid and effective method of delivering pain-relieving drugs, especially in emergency situations, where quick relief is crucial. Medications such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and other pain relievers can be administered via nasal delivery systems, providing fast absorption and immediate relief.

The convenience and speed of intranasal delivery for pain management, particularly in the treatment of acute pain, is driving the adoption of these devices. Furthermore, the rising demand for needle-free alternatives in pain treatment is further boosting the segment’s growth. As chronic pain conditions such as migraines and neuropathic pain become more prevalent, the market for intranasal pain management solutions is expected to expand.

Hospitals Remain the Dominant End-Use Industry due to the availability of advanced medical infrastructure

Hospitals continue to dominate the end-use industry for intranasal drug delivery devices, primarily due to the availability of advanced medical infrastructure and the high demand for efficient drug delivery systems. In hospital settings, intranasal devices are commonly used for the administration of pain relief medications, vaccines, and other urgent treatments. The ability to quickly deliver medications via nasal sprays and atomizers in critical care situations makes these devices indispensable in hospital environments.

Hospitals also play a significant role in the administration of intranasal vaccines, such as the flu vaccine, where convenience and patient compliance are essential. The ongoing improvements in hospital infrastructure and the increasing preference for non-invasive, needle-free alternatives are expected to keep hospitals as the largest end-use industry in this market.

Homecare Industry Sees Significant Growth due to the increasing preference for self-administration of intranasal drugs

The homecare segment is experiencing rapid growth due to the increasing preference for self-administration of intranasal drugs. With advancements in user-friendly devices, patients can now administer treatments for conditions like allergies, pain, and chronic diseases in the comfort of their homes. The convenience of intranasal drug delivery and the rising trend of home healthcare are fueling this growth.

In particular, chronic pain management and allergy treatments are seeing a shift toward homecare, as patients prefer the autonomy and ease of using intranasal devices at home. This trend is further supported by the growing demand for non-invasive, self-administered treatments, along with advancements in wearable and portable intranasal devices.

North America Dominates the Intranasal Drug Delivery Devices Market due to the Region's Well-Established Healthcare Infrastructure

North America leads the intranasal drug delivery devices market due to the region's well-established healthcare infrastructure, high prevalence of chronic diseases, and increasing patient preference for non-invasive treatments. The U.S. is a major contributor to the market growth, driven by advancements in medical technologies and widespread adoption of intranasal drug delivery systems across various therapeutic areas, including pain management and vaccination.

The presence of major pharmaceutical companies, regulatory support, and ongoing research into new intranasal drug delivery technologies are propelling market expansion in North America. Additionally, increasing healthcare expenditure and the rising demand for alternative drug delivery methods are expected to continue driving the market in this region.

Competitive Landscape and Key Players

The Intranasal Drug Delivery Devices Market is competitive, with leading players focusing on product innovations and expanding their market presence. Key companies in the market include Becton Dickinson and Company (BD), Johnson & Johnson, Mylan, Novartis, and GlaxoSmithKline, among others. These companies are investing heavily in research and development to enhance the effectiveness, ease of use, and safety of intranasal drug delivery systems.

Competitive strategies in the market include product launches, partnerships, and mergers and acquisitions. Companies are also exploring collaborations with research institutes and healthcare providers to develop novel drug formulations and delivery technologies. As the demand for non-invasive treatments continues to grow, the competition in the intranasal drug delivery devices market is expected to intensify, with key players striving to capture a larger share of the market.

Recent Developments:

• Johnson & Johnson launched an innovative intranasal spray for the rapid delivery of pain relief medication.
• AptarGroup, Inc. introduced a new line of nasal drug delivery devices with enhanced precision and ease of use.
• Merck & Co., Inc. received FDA approval for a nasal spray vaccine targeting seasonal influenza.
• Becton Dickinson and Company expanded its product offerings to include intranasal devices for non-invasive chronic disease management.
• Pfizer Inc. announced a strategic partnership to develop novel intranasal delivery devices for COVID-19 vaccines.

List of Leading Companies:

• Johnson & Johnson
• Meda AB (Acquired by Mylan)
• Becton Dickinson and Company (BD)
• AptarGroup, Inc.
• GlaxoSmithKline plc
• Novartis AG
• 3M Health Care
• Merck & Co., Inc.
• Pfizer Inc.
• Hovione
• Vapotherm, Inc.
• Teva Pharmaceuticals
• Procter & Gamble
• Bayer AG
• Antares Pharma, Inc.

Report Scope: